Dengue Vaccine

Pathophysiology And Challenges

• Dengue virus comprises four distinct serotypes.
• Natural infection confers lifelong homotypic immunity.
• Heterotypic immunity remains transient.
• Sub-neutralizing antibodies form complexes with dengue virus.
• Complexes paradoxically facilitate viral cell entry in host monocytes and macrophages.
• Phenomenon termed Antibody-Dependent Enhancement increases severe disease risk during secondary heterotypic infection.
• Vaccine must generate balanced neutralizing immunity against all four serotypes to prevent vaccine-related Antibody-Dependent Enhancement in seronegative individuals.

Licensed Vaccines

Dengvaxia

• Recombinant live-attenuated tetravalent vaccine.
• Utilizes yellow fever 17D virus backbone.
• Administered via three subcutaneous doses at 0, 6, and 12 months.
• Approved for ages 9-45 years.
• Pre-vaccination screening mandatory.
• Indicated strictly for individuals with laboratory-confirmed prior dengue infection.
• Seronegative recipients face heightened risk of severe dengue hospitalization due to Antibody-Dependent Enhancement.
• Efficacy remains higher against serotypes 3 and 4.

Qdenga

• Recombinant live-attenuated tetravalent vaccine.
• Utilizes dengue serotype 2 backbone.
• Administered via two subcutaneous doses 3 months apart.
• Indicated for adults, adolescents, and children older than 4 years.
• World Health Organization recommends administration for ages 6-16 in high-transmission settings.
• Sero-independent; pre-vaccination screening unnecessary.
• Efficacy reaches 80.9% overall and 95.4% against hospitalization at 12 months.
• Overall efficacy declines to 61.2% over 4.5 years.

Emerging Vaccines

Butantan-DV

• Live-attenuated chimeric tetravalent vaccine.
• Utilizes attenuated dengue serotype 4 backbone.
• Administered as single subcutaneous dose.
• Approved in Brazil for ages 12-59 years.
• Sero-independent administration.
• Demonstrates 80.5% effectiveness against severe dengue over 5 years.
• Achieves 100% protection against dengue-related hospitalizations.

V181

• Investigational quadrivalent vaccine currently in Phase 3 trials.
• Utilizes purified inactivated virus technology.
• Eliminates vaccine-induced viremia risk.
• Potentially safe for immunocompromised populations and pregnant women.

Comparative Analysis

Feature	Dengvaxia	Qdenga	Butantan-DV
Platform Backbone	Yellow fever 17D	Dengue serotype 2	Dengue serotype 4
Dosing Schedule	3 doses (0, 6, 12 months)	2 doses (0, 3 months)	Single dose
Target Age	9-45 years	>4 years	12-59 years
Serostatus Requirement	Strictly seropositive	Sero-independent	Sero-independent
Administration Route	Subcutaneous	Subcutaneous	Subcutaneous

Contraindications And Precautions

• Live-attenuated dengue vaccines contraindicated in immunocompromised individuals.
• Contraindicated in symptomatic human immunodeficiency virus infection.
• Contraindicated during pregnancy and lactation.
• Contraindicated in individuals with severe hypersensitivity to previous doses.